Novo Nordisk Begins Study of Lexicon Oral Obesity Drug

Novo Nordisk has initiated a study to evaluate the safety and tolerability of LX9851, an oral obesity drug, focusing on its physiological and biological effects as it moves through the body. This research is part of the company's ongoing efforts to expand its portfolio in the obesity treatment market.

The development of LX9851 is significant for Novo Nordisk as it seeks to enhance its offerings in a competitive landscape, particularly following recent approvals for higher doses of its existing weight-loss drug, Wegovy, which have shown promising results.

The introduction of LX9851 comes at a time when Novo Nordisk faces challenges, including declining sales projections and increasing competition from generic versions of its existing drugs like Ozempic and Wegovy, which are set to impact its market position in various regions.